TRCT
IMRX icon

Tower Research Capital (TRC)’s Immuneering IMRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3K Sell
2,672
-2,386
-47% -$12.1K ﹤0.01% 3860
2026
Q1 		$26.7K Buy
5,058
+4,951
+4,627% +$25.4K ﹤0.01% 3275
2025
Q4 		$704 Buy
+107
New +$687 ﹤0.01% 4841
2025
Q3 		– Sell
-2,984
Closed -$10.1K – 5404
2025
Q2 		$10.1K Sell
2,984
-3,344
-53% -$5.73K ﹤0.01% 3963
2025
Q1 		$9.62K Buy
6,328
+3,928
+164% +$7.13K ﹤0.01% 3751
2024
Q4 		$5.28K Buy
2,400
+432
+22% +$896 ﹤0.01% 4320
2024
Q3 		$4.9K Sell
1,968
-10,099
-84% -$14.7K ﹤0.01% 4382
2024
Q2 		$15.4K Buy
12,067
+7,174
+147% +$11.8K ﹤0.01% 3905
2024
Q1 		$14.1K Buy
4,893
+2,708
+124% +$15.2K ﹤0.01% 3334
2023
Q4 		$16.1K Sell
2,185
-1,063
-33% -$7.08K ﹤0.01% 3797
2023
Q3 		$24.9K Buy
3,248
+2,428
+296% +$22.3K ﹤0.01% 3174
2023
Q2 		$8.31K Sell
820
-1,948
-70% -$18.7K ﹤0.01% 4447
2023
Q1 		$27K Sell
2,768
-3,608
-57% -$20.5K ﹤0.01% 3109
2022
Q4 		$31K Buy
6,376
+3,659
+135% +$32.4K ﹤0.01% 2716
2022
Q3 		$39K Sell
2,717
-111
-4% -$881 ﹤0.01% 3377
2022
Q2 		$15K Buy
2,828
+1,312
+87% +$7K ﹤0.01% 4071
2022
Q1 		$10K Buy
1,516
+206
+16% +$1.98K ﹤0.01% 4312
2021
Q4 		$21K Buy
1,310
+1,077
+462% +$26.2K ﹤0.01% 3605
2021
Q3 		$6K Buy
+233
New +$6.26K ﹤0.01% 4753

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Tower Research Capital (TRC)'s IMRX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Immuneering (IMRX) stake by 47% in Q2 2026, selling an estimated $12.1K and leaving 2,672 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3860.

Tower Research Capital (TRC) first reported a position in IMRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $39K in Q3 2022. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Tower Research Capital (TRC) held 2,672 shares of Immuneering worth $13.3K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,386 Immuneering shares in Q2 2026, an estimated $12.1K.
  • Immuneering made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3860 holding.
  • Tower Research Capital (TRC) first reported a position in Immuneering in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Immuneering position peaked at $39K in Q3 2022.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.